WO1999022730A1 - Use of (+)-6-carboxamido-3-methylamino-1,2,3,4-tetrahydrocarbazole for treating hyperalgesia - Google Patents
Use of (+)-6-carboxamido-3-methylamino-1,2,3,4-tetrahydrocarbazole for treating hyperalgesia Download PDFInfo
- Publication number
- WO1999022730A1 WO1999022730A1 PCT/GB1998/003234 GB9803234W WO9922730A1 WO 1999022730 A1 WO1999022730 A1 WO 1999022730A1 GB 9803234 W GB9803234 W GB 9803234W WO 9922730 A1 WO9922730 A1 WO 9922730A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pain
- post
- tetrahydrocarbazole
- condition
- carboxamido
- Prior art date
Links
- 208000004454 Hyperalgesia Diseases 0.000 title claims description 21
- 208000035154 Hyperesthesia Diseases 0.000 title claims description 9
- 208000002193 Pain Diseases 0.000 claims abstract description 35
- 150000003839 salts Chemical class 0.000 claims abstract description 13
- 239000012453 solvate Substances 0.000 claims abstract description 12
- 230000035945 sensitivity Effects 0.000 claims abstract description 11
- 238000011282 treatment Methods 0.000 claims abstract description 11
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 claims description 8
- 239000004081 narcotic agent Substances 0.000 claims description 8
- 208000004296 neuralgia Diseases 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- 206010053552 allodynia Diseases 0.000 claims description 5
- 208000025978 Athletic injury Diseases 0.000 claims description 4
- 208000008035 Back Pain Diseases 0.000 claims description 4
- 206010058019 Cancer Pain Diseases 0.000 claims description 4
- 208000001387 Causalgia Diseases 0.000 claims description 4
- 208000035945 Labour pain Diseases 0.000 claims description 4
- 208000004983 Phantom Limb Diseases 0.000 claims description 4
- 206010056238 Phantom pain Diseases 0.000 claims description 4
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims description 4
- 208000004550 Postoperative Pain Diseases 0.000 claims description 4
- 208000010366 Postpoliomyelitis syndrome Diseases 0.000 claims description 4
- 206010041738 Sports injury Diseases 0.000 claims description 4
- 230000002917 arthritic effect Effects 0.000 claims description 4
- 238000002512 chemotherapy Methods 0.000 claims description 4
- 208000014439 complex regional pain syndrome type 2 Diseases 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 208000021722 neuropathic pain Diseases 0.000 claims description 4
- 208000030062 persistent idiopathic facial pain Diseases 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 238000011321 prophylaxis Methods 0.000 claims description 2
- 239000000679 carrageenan Substances 0.000 description 28
- 229920001525 carrageenan Polymers 0.000 description 28
- 229940113118 carrageenan Drugs 0.000 description 28
- 235000010418 carrageenan Nutrition 0.000 description 24
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 23
- 229960002284 frovatriptan Drugs 0.000 description 22
- SIBNYOSJIXCDRI-SECBINFHSA-N frovatriptan Chemical compound C1=C(C(N)=O)[CH]C2=C(C[C@H](NC)CC3)C3=NC2=C1 SIBNYOSJIXCDRI-SECBINFHSA-N 0.000 description 22
- 238000012360 testing method Methods 0.000 description 15
- 150000001875 compounds Chemical class 0.000 description 12
- 239000000203 mixture Substances 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 239000003981 vehicle Substances 0.000 description 8
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 208000019695 Migraine disease Diseases 0.000 description 4
- 150000004677 hydrates Chemical class 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 206010027599 migraine Diseases 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 229960003708 sumatriptan Drugs 0.000 description 4
- KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 239000003125 aqueous solvent Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000000018 receptor agonist Substances 0.000 description 3
- 229940044601 receptor agonist Drugs 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 239000004479 aerosol dispenser Substances 0.000 description 2
- 230000003070 anti-hyperalgesia Effects 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- CUETXFMONOSVJA-KLQYNRQASA-N butanedioic acid;(6r)-6-(methylamino)-6,7,8,9-tetrahydro-5h-carbazole-3-carboxamide;hydrate Chemical compound O.OC(=O)CCC(O)=O.N1C2=CC=C(C(N)=O)C=C2C2=C1CC[C@@H](NC)C2 CUETXFMONOSVJA-KLQYNRQASA-N 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 210000005166 vasculature Anatomy 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- XKLNOVWDVMWTOB-UHFFFAOYSA-N 2,3,4,9-tetrahydro-1h-carbazole Chemical class N1C2=CC=CC=C2C2=C1CCCC2 XKLNOVWDVMWTOB-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 235000003911 Arachis Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- 238000001061 Dunnett's test Methods 0.000 description 1
- 206010016059 Facial pain Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 206010028836 Neck pain Diseases 0.000 description 1
- 102000003797 Neuropeptides Human genes 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002460 anti-migrenic effect Effects 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 125000000609 carbazolyl group Chemical class C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 210000001627 cerebral artery Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000011340 continuous therapy Methods 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000026781 habituation Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000020341 sensory perception of pain Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to the treatment of hyperalgesia.
- the invention relates to the use of (+)-6-carboxamido-3- methylamino- 1,2,3,4- tetrahydrocarbazole (VML 251) in the treatment of conditions involving enhanced or exaggerated sensitivity to pain, such as hyperalgesia, causalgia and allodynia.
- PCT patent specification WO 93/00086 describes certain carbazole derivatives as 5-HT ⁇ -like receptor agonists having anti-migraine activity.
- (+)-6- carboxamido-3- methylarnino-l,2,3,4-tetrahydrocarbazole in the form of its succinate salt, described in PCT patent specification WO 94/14772 has been found to be particularly effective and is currently under clinical investigation as a potential therapy for migraine under the approved name frovatriptan (code number VML 251).
- This compound has a long duration of action and produces low incidence of side effects in migraine patients (Ryan & Keywood, 1997, Cephalalgia 17, 418).
- the receptor designation '5-HT ⁇ -like' has more recently been superseded by the term '5-HTIB/JD'.
- the exact mechanism by which 5-HTJB/JD receptor agonists exert their therapeutic effects in migraine is not known; current hypotheses suggest it involves constriction of cerebral arteries and or a direct inhibitory effect on release of neuropeptide from primary afferent nerve terminals.
- Conditions involving enhanced or exaggerated sensitivity to pain may occur in a variety of situations, eg following nerve or tissue damage.
- hyperalgesia refers to conditions wherein a painful stimulus is rendered more painful and allodynia to conditions wherein a non-painful stimulus is perceived to be painful.
- sumatriptan a 5-HT ⁇ / ⁇ receptor agonist commercially available for the treatment of migraine, possesses anti-hyperalgesic properties following morphine withdrawal (Ghelardini et al., 1996, Fund Clin Pharmacol 10, 192).
- sumatriptan was found to reduce pain but at a level which was not considered to be of clinical benefit (Harrison et al, 1997, Eur. Neuropsycholpharmacology 7: 83-88) .
- patients treated with sumatriptan experienced a variety of side effects, including: feelings of heaviness, warm/hot sensations, dryness of mouth, neck pain/stiffness and nausea and vomiting.
- frovatriptan exhibits antihyperalgesic activity in an animal model of carrageenan-induced thermal hyperalgesia.
- the present invention provides use of (+)-6-carboxamido-3- methylamino- 1,2,3, 4- tetrahydrocarbazole (frovatriptan) and physiologically acceptable salts, solvates and hydrates thereof in the treatment of conditions involving enhanced or exaggerated sensitivity to pain.
- Conditions involving enhanced or exaggerated sensitivity to pain include, but are not limited to, ongoing pain conditions such as atypical facial pain, neuropathic pain, back pain, complex regional pain syndromes I and II, arthritic pain, sports injury pain, pain related to infection e.g.
- HEN post-polio syndrome, post-herpetic neuralgia, phantom limb pain, labour pain, cancer pain, post-chemotherapy pain, post-stroke pain, post-operative pain, neuralgia, tolerance to narcotics or withdrawal from narcotics.
- frovatriptan produces a pharmacological profile which will provide clinically relevant pain relief in conditions involving enhanced or exaggerated sensitivity to pain.
- frovatriptan has a selective anti-vasodilatory effect against cerebral vasculature, not affecting coronary vasculature to any significant degree.
- the longer half-life of frovatriptan which results in a longer duration of action, make it particularly suitable for use in conditions of ongoing or long-lasting pain.
- (+)-6- carboxamido-3 - methylamino- 1 ,2,3 ,4-tetrahydrocarbazole frovatriptan
- physiologically acceptable salts, solvates and hydrates thereof in the manufacture of a medicament for use in conditions involving enhanced or exaggerated sensitivity to pain.
- a method for the treatment or prophylaxis of conditions involving enhanced or exaggerated sensitivity to pain in a subject which comprises administering to the subject an effective amount of (+)- 6-carboxamido-3- methylamino- 1, 2,3, 4-tetrahydrocarbazole (frovatriptan) or a physiologically acceptable salt, solvate or hydrate thereof.
- (+)-6-Carboxamido-3- methylamino- 1,2,3 ,4-tetrahydrocarbazole and its physiologically acceptable salts, solvates and hydrates may be prepared by methods known in the art for the preparation of tetrahydrocarbazoles, for example as described in PCT patent specification WO 93/00086 or WO 94/14772.
- (+)-6-carboxamido-3- methylamino- 1,2,3 ,4- tetrahydrocarbazole and its physiologically acceptable salts, solvates and hydrates are usually administered as a standard pharmaceutical composition comprising a compound of the invention and a physiologically acceptable carrier.
- the compounds for use according to the invention may be administered by any convenient method, for example by oral, parenteraL, buccal, inhalation, sublingual, nasal, rectal or transdermal administration and the pharmaceutical compositions adapted accordingly.
- the compounds for use according to the invention when given orally can be formulated as liquids, for example syrups, suspensions or emulsions, tablets, capsules and lozenges.
- a liquid formulation will generally consist of a suspension or solution of the compound or physiologically acceptable salt, solvate or hydrate in a suitable liquid carrier(s) for example an aqueous solvent such as water, ethanol or glycerine, or a non-aqueous solvent, such as polyethylene glycol or an oil.
- the formulation may also contain a suspending agent, preservative, flavouring or colouring agent.
- a composition in the form of a tablet can be prepared using any suitable pharmaceutical carrier(s) routinely used for preparing solid formulations.
- suitable pharmaceutical carrier(s) include magnesium stearate, starch, lactose, sucrose and cellulose.
- a composition in the form of a capsule can be prepared using routine encapsulation procedures.
- pellets containing the active ingredient can be prepared using standard carriers and then filled into a hard gelatin capsule; alternatively, a dispersion or suspension can be prepared using any suitable pharmaceutical carrier(s), for example aqueous gums, celluloses, silicates or oils and the dispersion or suspension then filled into a soft gelatin capsule.
- suitable pharmaceutical carrier(s) for example aqueous gums, celluloses, silicates or oils and the dispersion or suspension then filled into a soft gelatin capsule.
- Typical parenteral compositions consist of a solution or suspension of the compound or physiologically acceptable salt in a sterile aqueous carrier or parenterally acceptable oil, for example polyethylene glycol, polyvinyl pyrrolidone, lecithin, arachis oil or sesame oil.
- compositions for nasal administration may conveniently be formulated as aerosols, drops, gels and powders.
- Aerosol formulations typically comprise a solution or fine suspension of the active substance in a physiologically acceptable aqueous or non-aqueous solvent and are usually presented in single or multidose quantities in sterile form in a sealed container, which can take the form of a cartridge or refill for use with an atomising device.
- the sealed container may be a unitary dispensing device such as a single dose nasal inhaler or an aerosol dispenser fitted with a metering valve which is intended for disposal once the contents of the container have been exhausted.
- the dosage form comprises an aerosol dispenser
- a propellant which can be a compressed gas such as compressed air or an organic propellant such as a fluorochlorohydrocarbon.
- the aerosol dosage forms can also take the form of a pump-atomiser.
- compositions suitable for buccal or sublingual administration include tablets, lozenges and pastilles, wherein the active ingredient is formulated with a carrier such as sugar and acacia, tragacanth, or gelatin and glycerin.
- a carrier such as sugar and acacia, tragacanth, or gelatin and glycerin.
- compositions for rectal administration are conveniently in the form of suppositories containing a conventional suppository base such as cocoa butter.
- compositions suitable for transdermal administration include ointments, gels and patches.
- the composition is in unit dose form such as a tablet, capsule or ampoule.
- Each dosage unit for oral administration contains preferably from 0.1 to 250 mg, eg 1 to 250 mg (and for parenteral administration contains preferably from 0.01 to 25 mg, eg 0.1 to 25 mg) of a compound of the invention.
- the physiologically acceptable compounds for use according to the invention will normally be administered in a daily dosage regimen (for an adult patient) of, for example, an oral dose of between 0.1 and 500 mg, eg between 1 mg and 500 mg, preferably between 1 and 40 mg, eg between 1 and 10 mg, or an intravenous, subcutaneous, or intramuscular dose of between 0.1 mg and 100 mg, preferably between 0.1 mg and 50 mg, e.g. between 1 and 25 mg of the compound of the invention, the compound being administered 1 to 4 times per day.
- the compounds will be administered for a period of continuous therapy, for example for a week or more.
- a tablet for oral administration is prepared by combining.
- An injection for parenteral administration is prepared from the following:
- mice were placed in the test apparatus, for 10 min, once a day for three days for habituation. Withdrawal latencies of the left foot, to a focused, thermal stimulus (plantar test) were measured on separate days and the last measurement taken as a baseline. Carrageenan (2% w/v in saline, 0.25mls) was injected into the plantar surface of the left foot and withdrawal latencies measured (240 min post carrageenan).
- Frovatriptan was also tested in a mouse model of thermal nociception but was found to have no effect in that test.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU96373/98A AU9637398A (en) | 1997-10-31 | 1998-10-29 | Use of (+)-6-carboxamido-3-methylamino-1,2,3,4-tetrahydrocarbazole for treating hyperalgesia |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9723061.9 | 1997-10-31 | ||
GBGB9723061.9A GB9723061D0 (en) | 1997-10-31 | 1997-10-31 | Medicaments |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999022730A1 true WO1999022730A1 (en) | 1999-05-14 |
Family
ID=10821408
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1998/003234 WO1999022730A1 (en) | 1997-10-31 | 1998-10-29 | Use of (+)-6-carboxamido-3-methylamino-1,2,3,4-tetrahydrocarbazole for treating hyperalgesia |
Country Status (4)
Country | Link |
---|---|
AU (1) | AU9637398A (en) |
GB (1) | GB9723061D0 (en) |
WO (1) | WO1999022730A1 (en) |
ZA (1) | ZA989890B (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993000086A1 (en) * | 1991-06-26 | 1993-01-07 | Smithkline Beecham Plc | Use of tetrahydrocarbazone derivatives as 5ht1 receptor agonists |
WO1994014772A1 (en) * | 1992-12-21 | 1994-07-07 | Smithkline Beecham Plc | Enantiomers of carbazole derivatives as 5-ht1-like agonists |
WO1997025988A1 (en) * | 1996-01-17 | 1997-07-24 | Eli Lilly And Company | Methods of treating or preventing pain or nociception |
WO1997044062A1 (en) * | 1996-05-23 | 1997-11-27 | Alcon Laboratories, Inc. | The use of 5-ht1b/1d agonists to treat ocular pain |
-
1997
- 1997-10-31 GB GBGB9723061.9A patent/GB9723061D0/en not_active Ceased
-
1998
- 1998-10-29 WO PCT/GB1998/003234 patent/WO1999022730A1/en active Application Filing
- 1998-10-29 ZA ZA9809890A patent/ZA989890B/en unknown
- 1998-10-29 AU AU96373/98A patent/AU9637398A/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993000086A1 (en) * | 1991-06-26 | 1993-01-07 | Smithkline Beecham Plc | Use of tetrahydrocarbazone derivatives as 5ht1 receptor agonists |
WO1994014772A1 (en) * | 1992-12-21 | 1994-07-07 | Smithkline Beecham Plc | Enantiomers of carbazole derivatives as 5-ht1-like agonists |
WO1997025988A1 (en) * | 1996-01-17 | 1997-07-24 | Eli Lilly And Company | Methods of treating or preventing pain or nociception |
WO1997044062A1 (en) * | 1996-05-23 | 1997-11-27 | Alcon Laboratories, Inc. | The use of 5-ht1b/1d agonists to treat ocular pain |
Non-Patent Citations (5)
Title |
---|
"The next wave of migraine drugs", DIALOG FILE SUPPLIER: FILE 129: PHIND; AN=541406; SCRIP 2243, 24 June 1997 (1997-06-24), pages 23, XP002091296 * |
A.A. PARSONS ET AL.: "Comparison of the cardiovascular effects of the novel 5-HT1B/1D receptor agonist, SB209509 (VML251) and sumatriptan in dogs", JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, vol. 30, no. 1, July 1997 (1997-07-01), pages 136 - 141, XP002091297 * |
GHELARDINI, C. (1) ET AL: "Prevention by sumatriptan of hyperalgesia induced by morphine withdrawal.", FUNDAMENTAL & CLINICAL PHARMACOLOGY, (1996) VOL. 10, NO. 2, PP. 192. MEETING INFO.: 3RD JOINT MEETING OF THE SOCIETA ITALIANA DI FARMACOLOGIA AND THE FRENCH ASSOCIATION DES PHARMACOLOGISTES CAPRI, ITALY MAY 23-26, 1996 ISSN: 0767-3981., XP002091300 * |
HARRISON S.D. ET AL: "Atypical facial pain: A double-blind placebo-controlled crossover pilot study of subcutaneous sumatriptan.", EUROPEAN NEUROPSYCHOPHARMACOLOGY, (1997) 7/2 (83-88). REFS: 34 ISSN: 0924-977X CODEN: EURNE8, Netherlands, XP002091298 * |
ROBERTS-THOMSON I. ET AL: "Sumatriptan and episodic pain syndromes other than migraine [9].", PAIN, (1996) 67/1 (226-227). ISSN: 0304-3959 CODEN: PAINDB, Netherlands, XP002091299 * |
Also Published As
Publication number | Publication date |
---|---|
ZA989890B (en) | 2000-05-02 |
GB9723061D0 (en) | 1998-01-07 |
AU9637398A (en) | 1999-05-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2221563C2 (en) | Pharmaceutical composition for treatment of parkinson's disease and parkinson's syndrome, method for its preparing, method for treatment of parkinson's disease and parkinson's syndrome | |
CN104662007B (en) | Cystathionine gamma lyase (CSE) inhibitor | |
AU650706B2 (en) | Medicaments | |
JP2019089837A (en) | Pharmaceutical solutions, process of preparation, and therapeutic uses | |
CN100448439C (en) | Pharmaceutical compositions for headache, migraine, nausea and emesis | |
US20090325948A1 (en) | Inhibitors of undecaprenyl pyrophosphate synthase | |
RU2255736C2 (en) | Zolmitriptan-containing pharmaceutical composition | |
US4804669A (en) | Treatment of pain with a piperidine | |
JPH11501282A (en) | Epibatidine and its derivatives as cholinergic agonists and antagonists | |
AU2011293502A1 (en) | Methods for treating antipsychotic-induced weight gain | |
US20200093737A1 (en) | Pharmaceutical dosage forms containing task-1 and task-3 channel inhibitors, and the use of same in breathing disorder therapy | |
EA015483B1 (en) | Use of a p38 kinase inhibitor for treating psychiatric disorders | |
CA2362918A1 (en) | Methods and compositions for treating erectile dysfunction | |
WO1999022730A1 (en) | Use of (+)-6-carboxamido-3-methylamino-1,2,3,4-tetrahydrocarbazole for treating hyperalgesia | |
US5496823A (en) | Pharmaceutical composition for increasing bladder capacity | |
US6372763B1 (en) | Treatment and prevention of cardiac disorders using selective serotonin re-uptake inhibitors (SSRI) | |
WO2004082686A2 (en) | Use of compounds with combined 5-ht1a and ssri activities to treat sexual dysfunction | |
WO2005007191A1 (en) | Medicinal composition | |
CN100427484C (en) | 2-methoxymethyl-3-(3,4-dichlorophenyl)-8-azabicyclo[3.2.1]octane tartrate salts | |
JP2003327529A (en) | Antitussive agent and medicinal composition containing antitussive agent | |
JP2003171266A (en) | Antipyretic preparation containing xylitol | |
JPH07503240A (en) | Use of 3-arylindole and 1-arylindazole derivatives for the treatment of psychosis | |
US20020032192A1 (en) | Treatment of vasodilatory headache | |
RU2632718C2 (en) | Spray for oral application, containing choline alfoscerate | |
WO2024062443A1 (en) | Pharmaceutical compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: KR |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |